Prescription of Bempedoic Acid By General Practitioners in Dyslipidemic Patients Not At Target in Primary Prevention

Giuseppe Derosa^{1, 2,} , Pamela Maffioli¹, Angela D’Angelo^{3, 4}, Federico Naj⁵, Riccardo Naj⁵, Giorgio Rubino⁵, Matteo Bressani⁵, Luca Bellazzi⁵, Mario Giacometti⁵, Fortunato Capaccioni⁵ and Alessandro Rubino⁵

¹Centre of Diabetes and Metabolic Diseases, University of Pavia, and IRCCS Policlinico San Matteo Foundation, PAVIA, Italy

²Laboratory of Molecular Medicine, University of Pavia, PAVIA, Italy;Department of Internal Medicine and Therapeutics, University of Pavia, PAVIA, Italy

³Laboratory of Molecular Medicine, University of Pavia, PAVIA, Italy

⁴Department of Internal Medicine and Therapeutics, University of Pavia, PAVIA, Italy

⁵General Practictioner - ASST Pavia, PAVIA, Italy

Cite this paper:
Giuseppe Derosa, Pamela Maffioli, Angela D’Angelo, Federico Naj, Riccardo Naj, Giorgio Rubino, Matteo Bressani, Luca Bellazzi, Mario Giacometti, Fortunato Capaccioni and Alessandro Rubino. Prescription of Bempedoic Acid By General Practitioners in Dyslipidemic Patients Not At Target in Primary Prevention. American Journal of Medical Sciences and Medicine. 2025; 13(4):64-69. doi: 10.12691/ajmsm-13-4-3

Abstract

Background Dyslipidemia is a major risk factor for cardiovascular disease, and achieving LDL-C targets is crucial in primary prevention. However, many patients remain above target due to statin intolerance or inadequate response to therapy. This study evaluates the effectiveness of bempedoic acid, alone or with ezetimibe, in achieving LDL-C goals in a real-world primary prevention population managed by general practitioners (GPs). Methods A total of 254 dyslipidemic patients at moderate cardiovascular risk (LDL-C target: 100 mg/dl) were enrolled. 87.8% were statin-tolerant, while 10.2% were statin-intolerant. Patients received bempedoic acid alone or in combination with ezetimibe for nine months, and changes in lipid profile, glycemic parameters, and safety markers were assessed. Results LDL-C levels significantly decreased from 144.9 ± 27.3 mg/dl to 93.2 ± 11.6 mg/dl (p<0.01), successfully bringing all patients within the target of 100 mg/dl. Triglycerides (p= 0.71) did not decline significantly and TC (p<0.01) declined significantly, while FPG remained stable (−2.2%; p= 0.77). Notably, 61.4% of patients were prediabetic, making the neutral metabolic impact of bempedoic acid particularly relevant. The treatment was well tolerated, with no significant hepatic or muscular adverse effects. Conclusions Bempedoic acid, alone or with ezetimibe, effectively lowers LDL-C to guideline-recommended targets in primary prevention patients, including those with statin intolerance. The study highlights the key role of general practitioners in optimizing lipid management, reinforcing the importance of early and targeted interventions to reduce cardiovascular risk in real-world primary care settings.

Keywords:
Keywords: bempedoic acid hypercholesterolemia combined dyslipidemia general practitioner statin intolerance primary prevention

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk, Atherosclerosis, 290: 140-205, 2019.
[2]	Huang WC, Lin TW, Chiou KR, Cheng CC, Kuo FY, Chiang CH, Yang JS, Lin KL, Hsiao SH, Yeh TC, Mar GY, Hsiao HC, Lin SL, Chiou CW, Liu CP. The Effect of Intensified Low Density Lipoprotein Cholesterol Reduction on Recurrent Myocardial Infarction and Cardiovascular Mortality, Acta Cardiol Sin,29(5):404-412, 2013.
[3]	Ramkumar S, Raghunath A, Raghunath S. Statin Therapy: Review of Safety and Potential Side Effects, Acta Cardiol Sin, 32(6): 631-639, 2016.
[4]	Pedro-Botet J, Núñez-Cortés JM, Flores JA, Rius J. Muscle symptoms related with statin therapy in general practice, Atherosclerosis,241(1): e197, 2015.
[5]	Casula M, Gazzotti M, Bonaiti F, Olmastroni E, Arca M, Averna M, Zambon A, Catapano AL; PROSISA Study Group. Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study,J Intern Med,290(1):116-128, 2021.
[6]	Biolo G, Vinci P, Mangogna A, Landolfo M, Schincariol P, Fiotti N, Mearelli F, Di Girolamo FG. Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome, Front Cardiovasc Med, 9: 1028355, 2022.
[7]	Ray KK, Bays HE, Catapano AL, ND, LT, LR, PL, CM; . Safety and efficacy of bempedoic acid to reduce LDL cholesterol, N Engl J Med, 380(11):1022-1032, 2019.
[8]	Goldberg AC, Leiter LA, Stroes ESG, SJ, JC, LT, ND, PM, X, PB. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial, JAMA, 322(18):1780-1788, 2019.
[9]	Ballantyne CM, Banach M, Mancini GBJ, NE, JC, X, LA. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study, Atherosclerosis, 277:195-203, 2018.
[10]	Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, Kelly S, Stroes ESG. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance, J Am Heart Assoc, 8(7):e011662, 2019.
[11]	Nissen SE, Lincoff AM, Brennan D, KK, D, JJP, PD, P, L, J, HE, PM, V, DE, MJ, C-F, N, L, P, M, WJ, J, D, P, P, J, W, Y, SJ;CLEAROutcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients,N Engl J Med, 388(15):1353-1364, 2023.
[12]	Proposed International Guidelines for Biomedical Research Involving Human Subjects. The Council for International Organisation of Medical Sciences. Geneva, 1982.
[13]	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk,Eur Heart J, 41: 111-188, 2020.
[14]	Herman WH, Ye W. Precision prevention of diabetes, Diabetes Care, 46 (11): 1894-1896, 2023.
[15]	Derosa G, D’Angelo A, Maffioli P. The role of selected nutraceuticals in management of prediabetes and diabetes: An updated review of the literature,Phytother Res, 36 (10): 3709-3765, 2022.
[16]	National Institute for Health and Care Excellence. Obesity: identification, assessment and management, NICE 2022. Clinical Guideline, 189, 2022.
[17]	2023 ESH Guidelines for the management of arterial hypertension, J Hypertens, 41: 1874-2071, 2023.
[18]	European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus,Diabet Med, 16: 716-730, 1999.
[19]	Klose S, Borner K. EnzymatischeBestimmung des Gesamtcholesterinsmit dem [Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer (GSA II)], J Clin Chem Clin Biochem, 15: 121-130, 1978.
[20]	Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Methods of Enzymatic Analysis. Ed. H. U. Bergmeyer, 2nd English ed. Academic Press, New York (USA), pp. 18-31, 1974.
[21]	Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum, J Clin Invest, 34: 1345-1353, 1955.
[22]	Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of lowdensity lipoprotein in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18: 499-502, 1972.
[23]	Winer BJ. Statistical Principles in Experimental Design. 2nd ed, McGraw-Hill, New York, 1971.
[24]	Colivicchi F, Di Fusco SA, Scicchitano P, Caldarola P, Murrone A, Valente S, Urbinati S, Roncon L, Amodeo V, Aspromonte N, Cipriani M, Domenicucci S, Francese GM, Imazio M, Scotto di Uccio F, Di Lenarda A, Gulizia MM, Gabrielli D. J Cardiovasc Med (Hagerstown), 22(3): 162-171, 2021.
[25]	Banach M, Duell PB, Gotto Jr AM, Laufs U, Leiter LA, Mancini GBJ, Ray KK, Flaim J, Ye Z, Catapano AL. Association of bempedoicacid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia, JAMA Cardiol, 5(10); 1124-1135, 2020.
[26]	Leiter LA, Banach M, Catapano AL, Duell PB, AM, U, GBJ, KK, Hanselman JC, Ye Z, Bays HE. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials, DiabetesObesMetab, 24(5): 868-880, 2022.